Altre lingue AcuCort AB

Azioni

Prezzo di chiusura NORDIC GROWTH MARKET Altri mercati azionari 00:00:00 02/07/2024			Variaz. 5gg	Var. 1 gen.
0,776 ^SEK	-0,77%		-9,56%	+86,99%

26/04	AcuCort AB (publ) riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
16/04	AcuCort AB (publ) fornisce un aggiornamento sullo studio di Fase IV ZEQ001	CI

AcuCort: Zeqmelit® Planned to be Available in Pharmacies Starting September 1	01/07
Zeqmelit® Planned to be Available in Pharmacies Starting September 1	01/07
Very High Willingness to Pay for Zeqmelit® According to Publication in International Scientific Journal	11/06
Study on Patients' Willingness to Pay Published in an International Scientific Journal	21/05
The patient study on Zeqmelit® is fully recruited	13/05
AcuCort AB Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04
AcuCort publishes the annual report for 2023	17/04
Update on Phase IV Study: 40 of 50 Patients Recruited	16/04
AcuCort AB Provides Update on Phase IV Study ZEQ001	16/04
AcuCort's study to be published in an international scientific journal	26/03
Update on Phase 4 Study: 25 Patients Recruited	20/03
Insider trading in subscription option TO1 - CEO Jonas Jönmark increases his stake in AcuCort AB	11/03
Update on AcuCort's FDA Application ahead of Launch in the USA	07/03
AcuCort AB Announces Update on FDA Application Ahead of Launch in the USA	07/03
Acucort Lands First Zeqmelit Order from Unimedic Pharma	27/02
AcuCort AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	16/02
AcuCort Initiates Study for Acute Allergy Medication Zeqmelit	31/01
First patient using Zeqmelit® in study ahead of market launch	31/01
AcuCort AB Announces First Patient Using Zeqmelit in Study Ahead of Market Launch	31/01
AcuCort’s Oral Film Gains 10-year Trademark Protection in Switzerland	29/01

Non ci sono risultati per questa ricerca